MX2020005054A - Combinacion de dos agentes antivirales para el tratamiento de hepatitis c. - Google Patents
Combinacion de dos agentes antivirales para el tratamiento de hepatitis c.Info
- Publication number
- MX2020005054A MX2020005054A MX2020005054A MX2020005054A MX2020005054A MX 2020005054 A MX2020005054 A MX 2020005054A MX 2020005054 A MX2020005054 A MX 2020005054A MX 2020005054 A MX2020005054 A MX 2020005054A MX 2020005054 A MX2020005054 A MX 2020005054A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- antivirals
- combination
- treating hepatitis
- ribavirin
- Prior art date
Links
- 239000003443 antiviral agent Substances 0.000 title abstract 3
- 229940121357 antivirals Drugs 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 229940125782 compound 2 Drugs 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 229960000329 ribavirin Drugs 0.000 abstract 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a terapias libres de interferón y libres de ribavirina para el tratamiento del VHC. De preferencia, el tratamiento es de duración corta, tal como no más de 12 semanas. En un aspecto, el tratamiento comprende la administración de por lo menos dos agentes antivirales de acción di recta sin interferón ni ribavirina, a un sujeto con una infección por el VHC, en donde el tratamiento dura 12 semanas y los al menos dos agentes antivirales de acción di recta comprenden (a) el Compuesto 1 o una sal farmacéuticamente aceptable del mismo y (b) el Compuesto 2 o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361783376P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020005054A true MX2020005054A (es) | 2020-08-20 |
Family
ID=50588882
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018008084A MX373314B (es) | 2013-03-14 | 2014-03-14 | Combinacion de dos agentes antivirales para el tratamiento de hepatitis c. |
| MX2015012538A MX362616B (es) | 2013-03-14 | 2014-03-14 | Combinacion de dos agentes antivirales para el tratamiento de hepatitis c. |
| MX2020005054A MX2020005054A (es) | 2013-03-14 | 2015-09-11 | Combinacion de dos agentes antivirales para el tratamiento de hepatitis c. |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018008084A MX373314B (es) | 2013-03-14 | 2014-03-14 | Combinacion de dos agentes antivirales para el tratamiento de hepatitis c. |
| MX2015012538A MX362616B (es) | 2013-03-14 | 2014-03-14 | Combinacion de dos agentes antivirales para el tratamiento de hepatitis c. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20140275099A1 (es) |
| EP (3) | EP3766495A1 (es) |
| JP (4) | JP6441303B2 (es) |
| KR (2) | KR20210013344A (es) |
| CN (2) | CN105073113B (es) |
| AU (2) | AU2014239563B2 (es) |
| BR (1) | BR112015023017B1 (es) |
| CA (1) | CA2901810C (es) |
| CY (2) | CY1119025T1 (es) |
| DK (2) | DK3213750T3 (es) |
| EA (2) | EA201991174A1 (es) |
| ES (2) | ES2824473T3 (es) |
| HR (2) | HRP20171036T1 (es) |
| HU (2) | HUE033010T2 (es) |
| IL (1) | IL240419B (es) |
| LT (2) | LT3213750T (es) |
| MX (3) | MX373314B (es) |
| NZ (2) | NZ631155A (es) |
| PL (2) | PL2968301T3 (es) |
| PT (2) | PT3213750T (es) |
| RS (2) | RS56202B1 (es) |
| SG (2) | SG10201708306WA (es) |
| SI (2) | SI2968301T1 (es) |
| TW (2) | TWI642436B (es) |
| WO (1) | WO2014152514A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| SG10201708306WA (en) | 2013-03-14 | 2017-11-29 | Abbvie Inc | Combination of two antivirals for treating hepatitis c |
| JP2016523924A (ja) * | 2013-07-02 | 2016-08-12 | アッヴィ・インコーポレイテッド | Ｈｃｖの治療方法 |
| US20150119400A1 (en) * | 2013-10-25 | 2015-04-30 | Abbvie, Inc. | Methods for treating hcv |
| US20150174194A1 (en) * | 2013-12-19 | 2015-06-25 | Abbvie Inc. | Methods for treating liver transplant recipients |
| CA2942823C (en) * | 2014-04-02 | 2023-01-03 | Abbvie Inc. | Methods for treating hcv |
| AU2015240753B2 (en) * | 2014-04-02 | 2020-01-16 | Abbvie Inc. | Methods for treating HCV |
| BR112017028185A2 (pt) * | 2015-06-26 | 2018-09-04 | Abbvie Inc | composições farmacêuticas sólidas para tratar hcv |
| US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
| MX389088B (es) * | 2015-07-08 | 2025-03-20 | Abbvie Inc | Métodos para tratar el vhc. |
| US20230385268A1 (en) * | 2022-05-17 | 2023-11-30 | Abbvie Inc. | Methods for Treating HCV |
| SG10202002900YA (en) * | 2015-07-17 | 2020-05-28 | Abbvie Inc | Solid pharmaceutical compositions for treating hcv |
| EP3448392A4 (en) | 2016-04-28 | 2020-01-15 | Emory University | ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS |
| WO2018057919A1 (en) * | 2016-09-23 | 2018-03-29 | Abbvie Inc. | Dose adjustment |
| CA2994496A1 (en) * | 2017-02-14 | 2018-08-14 | Abbvie Inc. | Methods for treating hcv |
| CA2981993A1 (en) * | 2017-08-02 | 2019-02-02 | Abbvie Inc. | Methods for treating hcv |
| EP3773753A4 (en) * | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS |
| CA3120686A1 (en) | 2018-11-20 | 2020-05-28 | Abbvie Inc. | Methods for treating acute hcv |
| KR102077833B1 (ko) | 2018-12-10 | 2020-02-14 | 류형준 | 기능성 식품조성물 |
| CN111688355B (zh) | 2019-03-15 | 2022-04-12 | 精工爱普生株式会社 | 液体吸收体、液体吸收器以及液体喷出装置 |
| CN113645958A (zh) * | 2019-04-08 | 2021-11-12 | 艾伯维公司 | 用于治疗hcv的固体药物组合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9394279B2 (en) * | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8937150B2 (en) * | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| EP2618831B1 (en) * | 2010-09-21 | 2016-01-06 | Enanta Pharmaceuticals, Inc. | Macrocyclic proline derived hcv serine protease inhibitors |
| US8330139B2 (en) | 2011-03-25 | 2012-12-11 | Micron Technology, Inc. | Multi-level memory cell |
| CA2811250C (en) | 2011-10-21 | 2015-08-11 | Abbvie Inc. | Methods for treating hcv |
| SE1450019A1 (sv) | 2011-10-21 | 2014-01-10 | Abbvie Inc | Förfaranden för att behandla HCV innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon |
| HRP20191939T1 (hr) * | 2012-09-18 | 2020-01-10 | Abbvie Inc. | Postupci za liječenje hepatitisa c |
| SG10201708306WA (en) | 2013-03-14 | 2017-11-29 | Abbvie Inc | Combination of two antivirals for treating hepatitis c |
-
2014
- 2014-03-14 SG SG10201708306WA patent/SG10201708306WA/en unknown
- 2014-03-14 EP EP20183791.1A patent/EP3766495A1/en active Pending
- 2014-03-14 TW TW103109530A patent/TWI642436B/zh not_active IP Right Cessation
- 2014-03-14 HR HRP20171036TT patent/HRP20171036T1/hr unknown
- 2014-03-14 KR KR1020217002760A patent/KR20210013344A/ko not_active Withdrawn
- 2014-03-14 MX MX2018008084A patent/MX373314B/es unknown
- 2014-03-14 EP EP17165207.6A patent/EP3213750B1/en active Active
- 2014-03-14 NZ NZ631155A patent/NZ631155A/en unknown
- 2014-03-14 BR BR112015023017-2A patent/BR112015023017B1/pt active IP Right Grant
- 2014-03-14 JP JP2016502431A patent/JP6441303B2/ja active Active
- 2014-03-14 EA EA201991174A patent/EA201991174A1/ru unknown
- 2014-03-14 AU AU2014239563A patent/AU2014239563B2/en active Active
- 2014-03-14 SI SI201430265A patent/SI2968301T1/sl unknown
- 2014-03-14 HU HUE14719977A patent/HUE033010T2/en unknown
- 2014-03-14 DK DK17165207.6T patent/DK3213750T3/da active
- 2014-03-14 DK DK14719977.2T patent/DK2968301T3/en active
- 2014-03-14 US US14/210,870 patent/US20140275099A1/en not_active Abandoned
- 2014-03-14 CN CN201480015311.3A patent/CN105073113B/zh not_active Expired - Fee Related
- 2014-03-14 LT LTEP17165207.6T patent/LT3213750T/lt unknown
- 2014-03-14 WO PCT/US2014/027423 patent/WO2014152514A1/en not_active Ceased
- 2014-03-14 RS RS20170672A patent/RS56202B1/sr unknown
- 2014-03-14 SG SG11201507364SA patent/SG11201507364SA/en unknown
- 2014-03-14 CN CN201810067970.1A patent/CN108159393A/zh active Pending
- 2014-03-14 LT LTEP14719977.2T patent/LT2968301T/lt unknown
- 2014-03-14 HU HUE17165207A patent/HUE052113T2/hu unknown
- 2014-03-14 ES ES17165207T patent/ES2824473T3/es active Active
- 2014-03-14 PT PT171652076T patent/PT3213750T/pt unknown
- 2014-03-14 MX MX2015012538A patent/MX362616B/es active IP Right Grant
- 2014-03-14 PL PL14719977T patent/PL2968301T3/pl unknown
- 2014-03-14 CA CA2901810A patent/CA2901810C/en active Active
- 2014-03-14 SI SI201431674T patent/SI3213750T1/sl unknown
- 2014-03-14 KR KR1020157029549A patent/KR102210935B1/ko active Active
- 2014-03-14 NZ NZ719137A patent/NZ719137A/en unknown
- 2014-03-14 TW TW107108651A patent/TWI686196B/zh not_active IP Right Cessation
- 2014-03-14 EP EP14719977.2A patent/EP2968301B1/en not_active Revoked
- 2014-03-14 PL PL17165207T patent/PL3213750T3/pl unknown
- 2014-03-14 RS RS20201198A patent/RS60881B1/sr unknown
- 2014-03-14 ES ES14719977.2T patent/ES2624980T3/es active Active
- 2014-03-14 EA EA201591702A patent/EA033257B1/ru unknown
- 2014-03-14 PT PT147199772T patent/PT2968301T/pt unknown
-
2015
- 2015-08-06 IL IL240419A patent/IL240419B/en active IP Right Grant
- 2015-09-11 MX MX2020005054A patent/MX2020005054A/es unknown
-
2016
- 2016-05-03 AU AU2016202823A patent/AU2016202823B2/en active Active
-
2017
- 2017-06-21 CY CY20171100653T patent/CY1119025T1/el unknown
-
2018
- 2018-11-22 JP JP2018219054A patent/JP6621902B2/ja active Active
-
2019
- 2019-11-19 JP JP2019208502A patent/JP2020037589A/ja active Pending
-
2020
- 2020-10-05 HR HRP20201575TT patent/HRP20201575T1/hr unknown
- 2020-10-05 CY CY20201100930T patent/CY1123387T1/el unknown
-
2021
- 2021-06-07 JP JP2021094935A patent/JP2021130720A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020005054A (es) | Combinacion de dos agentes antivirales para el tratamiento de hepatitis c. | |
| PH12014502848A1 (en) | Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon | |
| MX388482B (es) | Métodos para tratar el virus de la hepatitis c. | |
| PH12014502847A1 (en) | Combination treatment (eg with abt-072-333) of daas for use in treating hcv | |
| PH12018550201A1 (en) | Hepatitis b antiviral agents | |
| EA201890507A1 (ru) | Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv | |
| PH12018550148A1 (en) | Hepatitis b antiviral agents | |
| PH12018550150B1 (en) | Elimination of hepatitis b virus with antiviral agents | |
| EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
| MX2015017953A (es) | Metodos para tratar el virus de hepatitis c. | |
| MX2018000240A (es) | Metodos para tratar el vhc. | |
| RU2015114566A (ru) | Способы лечения гепатита с | |
| MX2016012722A (es) | Metodos para tratar el virus de la hepatitis c. | |
| MX2020001422A (es) | Metodos para el tratamiento de hcv. | |
| MX2018001905A (es) | Metodos para el tratamiento del virus de hepatitis c (vhc). | |
| EA201491652A1 (ru) | Средство для лечения вирусного гепатита с | |
| AU2019384793A8 (en) | Methods for treating acute HCV | |
| WO2014122537A3 (en) | Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin | |
| ES2572355A2 (es) | Combinacion de aad para uso en el tratamiento del vhc | |
| NZ631789A (en) | Combination of direct acting antiviral agents and ribavirin for treating hcv patients | |
| EA201892004A1 (ru) | Противовирусные средства для лечения гепатита b |